计算溶液所需的质量、体积或浓度。
| 活性类型 | Relation | Activity value | Units | Action Type | 期刊 | PubMed Id | doi | Assay Aladdin ID |
|---|
Moligand™ 级 提供 ≥98% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 1 篇同行评审文献引用。
Temuterkib (LY3214996)是一种选择性、新型ERK1/2抑制剂,抑制ERK1和ERK2的IC50为5 nM。在具有BRAF和RAS突变的癌细胞系中,它能有效地抑制细胞内p-RSK1。
Information
LY3214996 LY3214996 is a selective and novel ERK1/2 inhibitor with IC50 of 5 nM for both enzymes in biochemical assays. It potently inhibits cellular phospho-RSK1 in BRAF and RAS mutant cancer cell lines.
Targets
ERK1 (Cell-free assay); ERK2 (Cell-free assay) 5 nM; 5 nM
In vitro
In an unbiased tumor cell panel sensitivity profiling for inhibition of cell proliferation, tumor cells with MAPK pathway alterations including BRAF, NRAS or KRAS mutation are generally sensitivity to LY3214996. LY3214996 possesses an optimal balance of potency (hERK1 IC50 5 nM, hERK2 IC50 5nM, pRSK IC50 0.43 µM) and solubility.
In vivo
In tumor xenograft models, LY3214996 inhibits PD biomarker phospho-p90RSK1 in tumors and the PD effects are correlated with compound exposures and anti-tumor activities. LY3214996 shows either similar or superior anti-tumor activity as compared to other published ERK inhibitors in BRAF or RAS mutant cell lines and xenograft models. Oral administration of single-agent LY3214996 significantly inhibits tumor growth in vivo and is well tolerated in BRAF or NRAS mutant melanoma, BRAF or KRAS mutant colorectal, lung and pancreatic cancer xenografts or PDX models. In addition, LY3214996 has anti-tumor activity in a vemurafenib-resistant A375 melanoma xenograft model due to MAPK reactivation, may have potential for treatment of melanoma patients who have failed BRAF therapies. More importantly, LY3214996 can be combined with investigational and approved agents in preclinical models, particularly KRAS mutant models. Combination treatment of LY3214996 and CDK4/6 inhibitor abemaciclib is well tolerated and results in potent tumor growth inhibition or regression in multiple in vivo cancer models, including KRAS mutant colorectal and non-small cell lung cancers. LY3214996 has good PK properties (dog, AUCoral 23800 nM*hr, CL 12.1 mL/min/kg, bioavailability 75.4%), IVTI (TED50 =16 mg/kg pRSK1) and demonstrates significant in vivo efficacy in several human cancer xenograft models.
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 有机杂环化合物 |
| 类(Class) | 噻吩类 |
| 亚类(Subclass) | 2,3,5-三取代噻吩 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | 2,3,5-三取代噻吩 |
| 其他上位类(Alternative Parents) | 氨基嘧啶及其衍生物 吗啉 叔羧酸酰胺 吡唑类 杂芳族化合物 三烷基胺 内酰胺类 氨基酸及其衍生物 仲胺 氧环化合物 二烷基醚 氮杂环化合物 有机光子化合物 有机氧化物 碳氢化合物衍生物 |
| 分子骨架(Molecular Framework) | 芳香族杂多环化合物 |
| 取代基(Substituents) | 2,3,5-三取代噻吩 - 氨基酸 - 氨基酸或其衍生物 - 氨基吡啶 - 芳香族杂多环化合物 - 氮杂环 - 吡唑 - 羧酰胺基 - 羧酸衍生物 - 二烷基醚 - 乙醚 - 杂芳香族化合物 - 烃衍生物 - 肟 - Morpholine - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机氮化合物 - 有机氧化合物 - 有机氮化合物 - 氧杂环 - 氧杂吡嗪烷 - 吡唑 - 嘧啶 - 醛基 - 三元脂肪胺 - 三芳基胺 - 叔羧酸酰胺 |
| 描述(Description) | 该化合物属于有机化合物中的2,3,5-三取代噻吩类。这类有机化合物含有在C-2、C-3和C-5位点均被取代的噻吩结构。 |
| 外部描述符(External Descriptors) | 暂无 |
| ALogP | 2.664 |
|---|---|
| hba_count | 5 |
| HBD Count | 1 |
| Rotatable Bond | 6 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
H302: 吞食有害
H315: 引起皮肤刺激
H319: 引起严重眼睛刺激
H335: 可能引起呼吸道刺激
P261: 避免吸入灰尘/烟雾/气体/雾/蒸汽/喷雾
P305+P351+P338: 如进入眼睛:用水小心冲洗几分钟。如戴隐形眼镜并可方便地取出,取出隐形眼镜。继续冲洗。